{"id":926065,"date":"2026-01-11T17:03:33","date_gmt":"2026-01-11T22:03:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/"},"modified":"2026-01-11T17:03:33","modified_gmt":"2026-01-11T22:03:33","slug":"day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/","title":{"rendered":"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 &#8211; $250 million<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET)<\/em>\n      <\/p>\n<p>BRISBANE, Calif., Jan.  11, 2026  (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (\u201cDay One\u201d or the \u201cCompany\u201d), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the release of preliminary unaudited 2025 OJEMDA\u2122 net product revenue, cash and investments at year-end and provided 2026 OJEMDA net product revenue guidance ahead of the company\u2019s scheduled presentation tomorrow at the 44th\u00a0Annual J.P. Morgan Healthcare Conference at 5:15 pm PT (8:15 pm ET).<\/p>\n<p>\u201cFollowing remarkable commercial and clinical progress in 2025 and the strategic acquisition of Mersana and our new pipeline program Emi-Le (emiltatug ledadotin), we\u2019re entering 2026 poised to deliver on our mission and on our growth aspirations,\u201d said Jeremy Bender, Ph.D., chief executive officer of Day One.\u00a0\u201cI\u2019m thrilled by the steady uptake of OJEMDA in relapsed or refractory pLGG, and by the opportunities for future patient impact we expect from the clinical data for OJEMDA in front line pLGG and for Emi-Le and DAY301. Our solid financial position will continue to enable us to invest in future programs that have strong potential to become important new medicines.\u201d<\/p>\n<p>\n        <strong>2025 OJEMDA Commercial Performance<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>OJEMDA net product revenue was approximately $52.8 million and $155.4 million for the fourth quarter and full year 2025, respectively (unaudited)<\/li>\n<li>~37% QoQ growth compared to Q3 2025; ~172% YoY growth vs. 2024, driven by momentum in patient demand, with prescription volumes increasing to 1,394 during the fourth quarter<\/li>\n<li>2026 OJEMDA U.S. net product revenue is projected to be between $225 million and $250 million, representing 53% year-over-year growth at the midpoint<\/li>\n<\/ul>\n<p>\n        <strong>2026 Corporate Priorities and Key Milestones <\/strong>\n      <\/p>\n<p>\n        <strong>OJEMDA <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Deliver on 2026 OJEMDA net product revenue guidance, with a focus on increasing persistency and driving new patient starts to support continued OJEMDA adoption as standard of care (SOC) in 2L pediatric low-grade glioma (pLGG)<\/li>\n<li>Extend the OJEMDA commercial opportunity beyond the U.S. with global expansions via our partner<\/li>\n<li>Complete enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial in first-line pLGG in the first half of 2026, enabling a mid-2027 data readout and a potential approval in 2028<\/li>\n<\/ul>\n<p>\n        <strong>PIPELINE<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Advance Emi-Le program by delivering Phase 1 clinical data by mid-2026 and progressing toward registration<\/li>\n<li>Provide initial data from the Phase 1a clinical trial for DAY301, a PTK7-targeted antibody drug conjugate (ADC), in the second half of 2026<\/li>\n<\/ul>\n<p>\n        <strong>Corporate Update<\/strong><br \/>\n        <br \/>As of December 31, 2025, prior to the acquisition of Mersana, Day One had approximately $441.1 million of cash, cash equivalents, and short-term investments (unaudited). The 2025 net product revenues and cash, cash equivalents and short-term investments position included in this release are preliminary and are therefore subject to adjustment. The preliminary net product revenue results are based on management\u2019s initial analysis of operations for the year ended December 31, 2025. The Company expects to issue full financial results for the fourth-quarter and full-year 2025 in February 2026.<\/p>\n<p>\n        <strong>J.P. Morgan Presentation Details<\/strong><br \/>\n        <br \/>Dr. Jeremy Bender, chief executive officer, will present during the 44<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 pm PT (8:15 pm ET). A live audio webcast of the presentation will be available by visiting the Events &amp; Presentations section of the Company\u2019s website at\u00a0www.dayonebio.com. An archived replay of the webcast will be available for 30 days following the live presentation.<\/p>\n<p>\n        <strong>About Day One Biopharmaceuticals <\/strong><br \/>\n        <br \/>Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by \u201cThe Day One Talk\u201d that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what\u2019s possible for all people living with cancer\u2014regardless of age\u2014starting from Day One.<\/p>\n<p>Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company\u2019s pipeline includes tovorafenib (OJEMDA\u2122), DAY301, and following the recently announced acquisition of Mersana Therapeutics, Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).<\/p>\n<p>Day One is based in Brisbane, California. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZV65WYSvEE0ub9bI2zG86hEcm8Ino-WccBUGs6dZb-CzfJ8Cj56ljkXmLQUtc2o2YsiWa34FyqpHM65cdLgnopiMWKtepLjqik7p3-ODTwaqbDqVmED57Evzl_P4_k3JxRLFZdzNmoUF5r86MsKLQqn0mxWJp5mBVAhHIQHROvBqKPj5K4LdD1sFn2kBvvmiD9ZX4Dv4-GA6ruQPUX1svuQD_MhNjzruz_MaW_Dg3ic4ImZObNbK1dt2vW32ZvrjWn9AejDOe-gRdB2VInLeRg==\" rel=\"nofollow\" target=\"_blank\">www.dayonebio.com<\/a>\u00a0or find the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hxfVYP3nKjU33e10pzkVBfWYwpBuT4Qp7NOPGVsSgYaquOP7TdC3aWYSteBEMGKxSoDbgt2Ys0sOz6Vx9kTQcFXjabK07KzgdzQOnT2vnQ0ngQkRd2d4Thap_0CICegzqRbwDnV8Rd3Gk1h15fdHfwFUx38rOJyxoRWrLhTAlgVjny87VIDAeVU2ZACvytgltBRj8vKIvgFyUHVeuOjcDrD_-srCcQrz_FFTy82utS99--gNXbrhG7u9-Xl6i-s3\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rWxp77fGpWa7rUU6xe02A0srX_kk65eILKkqa7EIzGgNGmSXiyyy1OdAa2n2BNXGd3-6-bzrZjEm2TSAVCvS2GaQUBBYFJxVG8CKCvda9JGNZWzFPyMhAT7sy3XMzdpNfy6v6GIoWZJ58-uBwfd0szWneXl9sfwu60bZct35BvS163YLuElQZNWFW2xJHtreDYEKEn7ZQoo5fbtZOR-gsA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking\u201d statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Day One\u2019s ability to grow revenue from OJEMDA, plans to develop and commercialize cancer therapies and its pipeline and the impact of Emi-Le and DAY301, and statements regarding its net product revenues, cash, cash equivalents and short-term investments. Statements including words such as \u201cbelieve,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cdevelop,\u201d \u201csignal,\u201d \u201cpotential,\u201d or \u201congoing\u201d and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.<\/p>\n<p>Forward-looking statements are subject to risks and uncertainties that may cause Day One\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including risks related to the ability to realize the anticipated benefits of the Mersana acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of the consummation of the acquisition on the market price of Day One\u2019s common stock and\/or operating results; significant transaction costs; unknown liabilities, Day One\u2019s ability to develop, obtain and retain regulatory approval for or commercialize any product candidate, Day One\u2019s ability to protect intellectual property, the potential impact of global business or macroeconomic conditions, including as a result of inflation, government shutdowns, rising interest rates, instability in the global banking system, geopolitical conflicts and the sufficiency of Day One\u2019s cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\n        <strong>DAY ONE MEDIA<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gqx8Bh6a1vFcxRO2YDknWLBeifJaIFVGZNkNfogFp2kb6Bxd1F-AqDK_XlwDW1Kqoz-j0Z_1ry1L9qgHbxT64gA5s8D7Q2aLOl7AwgowTo=\" rel=\"nofollow\" target=\"_blank\">media@dayonebio.com<\/a>\n      <\/p>\n<p>\n        <strong>DAY ONE INVESTORS<\/strong><br \/>\n        <br \/>LifeSci Advisors, PJ Kelleher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OBezkdnALDqqGAeaqvWwB1Sp6VjFwKHlkkJkh03iwcGiOm21j0-NJQhfe8MimH0DrENGIbusIfw3G4kyKCfbD2hl5X9XuP3vH8V4VSBfS1J3UYyYoO24T7LVtJcOu2El\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmQ5YTA2NDMtNjc0Zi00OTZmLTk2OWYtMzE4NmE0Yzk1ODg2LTEyMjA3MTQtMjAyNi0wMS0xMS1lbg==\/tiny\/Day-One-Biopharmaceuticals-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 &#8211; $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (\u201cDay One\u201d or the \u201cCompany\u201d), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the release of preliminary unaudited 2025 OJEMDA\u2122 net product revenue, cash and investments at year-end and provided 2026 OJEMDA net product revenue guidance ahead of the company\u2019s scheduled presentation tomorrow at the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926065","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 &#8211; $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (\u201cDay One\u201d or the \u201cCompany\u201d), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the release of preliminary unaudited 2025 OJEMDA\u2122 net product revenue, cash and investments at year-end and provided 2026 OJEMDA net product revenue guidance ahead of the company\u2019s scheduled presentation tomorrow at the &hellip; Continue reading &quot;Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T22:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance\",\"datePublished\":\"2026-01-11T22:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/\"},\"wordCount\":1160,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/\",\"name\":\"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=\",\"datePublished\":\"2026-01-11T22:03:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/","og_locale":"en_US","og_type":"article","og_title":"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Market Newsdesk","og_description":"Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 &#8211; $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (\u201cDay One\u201d or the \u201cCompany\u201d), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the release of preliminary unaudited 2025 OJEMDA\u2122 net product revenue, cash and investments at year-end and provided 2026 OJEMDA net product revenue guidance ahead of the company\u2019s scheduled presentation tomorrow at the &hellip; Continue reading \"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-11T22:03:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance","datePublished":"2026-01-11T22:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/"},"wordCount":1160,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/","name":"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=","datePublished":"2026-01-11T22:03:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzQ3MSM3MzU1MDQwIzIyMDkxNjE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-preliminary-2025-ojemda-net-product-revenue-and-provides-2026-net-product-revenue-guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Day One Announces Preliminary 2025 OJEMDA\u2122 Net Product Revenue And Provides 2026 Net Product Revenue Guidance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926065"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926065\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}